

POTENTIAL ANTIMICROBIAL ACTIVITY OF SOME NEW 3,5-DIMETHYL PYRAZOLE DERIVATIVES

Anca Mihaela MOCANU* and Constantin LUCA

“Gheorghe Asachi” Technical University of Iasi, Faculty of Chemical Engineering and Environmental Protection, 71 A D. Mangeron Ave, 700050, Iasi, Romania

Abstract

The study presents original contributions to the researches developed in the class of heterocyclic derivatives with potential biological activity. The objective of this study is to evaluate antibacterial activity of new derivatives synthesized. Synthesis was done by obtaining new molecules with pyrazolone structure which combine two pharmacore entities: the amidosulfonyl-R1,R2 phenoxyacetil with the 3,5-dimethyl pyrazole which can have potential biological properties. The microbial properties were confirmed by the microbiological tests. The synthesized compounds were evaluated by measuring zone diameters of bacterial growth inhibition on different types of strains microorganisms: Staphylococcus aureus, Escherichia coli and Candida Albicans.

Keywords: *derivates of pyrazole, microorganisms, difusimetric method, antimicrobial activity.*

Introduction

Among the non-steroid anti-inflammatory compounds the pyrazol derivatives are known as a particularly important class recommended in treating the muscle pains, fever states and arthritis. These compounds are mentioned in recent literature to show not only analgesic and anti-inflammatory effects but also anti-tumor, anti-microbial, anti-oxidative, hypoglycemic and anti-convulsive proprieties bringing thus new potential therapeutic indications into discussion [1-5].

The anti-microbial properties are due to the ability of some constituents of destroying the infectious agents and preventing from their proliferation inside the organisms and environment. Thus, a multitude of such compounds are investigated for their potential applications as therapeutic agents in treating infectious diseases especially those caused by the multi-resistant bacteria [4-6].

The discovery of new therapeutic representatives showing improved pharmacologic profile and therapeutic safety is a major concern of many researchers. The researches reported in the present study are directed to this field being aimed to obtain new heterocyclic derivatives with potential biological activity [5-7].

The novelty and originality of the studies achieved in the present paper consist in the antimicrobial activities of new products which are not mentioned in literature showing potential pharmaceutical [8-10].

The antimicrobial activities of the newly obtained compounds were estimated against a Gram-positive (*Staphylococcus aureus*) and Gram-negative (*Escherichia coli*) bacteria and on yeasts (*Candida albicans*).

The comparative inhibiting action was estimated by the difusimetric method in the overlay agar (for bacteria) and Sabouraud (for yeasts). The measured critical diameters afford the germs under study to be classified as “sensitive” and “resistant”. The obtained results were expressed by the direct transcription of the inhibition area diameter [11].


The new derivatives were synthesized according to the method described in our previous paper [14].

The newly analyzed compounds and their denominations data are given in Fig. 2.


There are different levels of sensitivity to the tested compounds against of the microorganisms (Table 1).

Table 1. The levels of sensitivity to the tested compounds


Microorganism tested	1	2	3	Standard (DMSO)
Staphylococcus aureus	6	17	8	0
Escherichia coli	32	45	40	0
Candida albicans	11	16	20	0



1-(2-methyl, 4-buthyl-amidosulfonyl)-phenoxyacetyl-3,5-dimethyl pyrazole (1)
 Chemical formula: $C_{18}H_{25}N_3O_4S$
 Molecular weight: 379
 Melting point: 141-143 °C



1-(2-chloro, 4-ethyl-amidosulfonyl)-phenoxyacetyl-3,5-dimethyl pyrazole (2)
 Chemical formula: $C_{15}H_{18}N_3O_7S$
 Molecular weight: 371.5
 Melting point: 186-188 °C



1-(2-methyl, 4-dibutyl-amidosulfonyl)-phenoxyacetyl-3,5-dimethyl pyrazole (3)
 Chemical formula: $C_{22}H_{35}N_3O_4S$
 Molecular weight: 437
 Melting point: 136-138 °C

Fig. 2. Structures of new compounds

The research results prove the antibacterial action of the three compounds tested against microorganisms.

The anti-bacterial activity was made evident for the compounds, with the *Staphylococcus aureus* species where the inhibition area diameters were of rather close values (6 mm for compound 1 and 8 mm for compound 3) while compound (2) a show pronounced anti-bacterial effect.

In the case of testing the antibacterial action of compounds there was highlighted a greater sensitivity of Gram-negative bacteria (*Escherichia coli*) compared with Gram-positive bacteria (*Staphylococcus aureus*), phenomenon given by the presence of substitutes of chlorine and methyl type of compound, which can obviously influence the growth and spreading of this microorganisms.

Also, compounds (2) and (3) influence, differentially the development of the microorganisms, antibacterial activity being obvious in case of Gram-negative bacteria which presents a higher level of sensitivity to chlorine groups from compound (2) and substitutes of methyl from compound (3). As revealed by the data obtained with the *Escherichia coli* species all the tested compounds showed antibacterial action decreasing in the following order: 2<3<1 (Table 1).

The inhibition diameter zones vary between 32-45 mm in case of *Escherichia coli* species and 6-17 mm in case testing the *Staphylococcus aureus* species (Table 1).




Fig. 3. Testing of the antimicrobial action against *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans*

With *Candida albicans* the inhibition area diameters were different, especially for compound (2) -16 mm and (3) - 20 mm, while a slighter inhibition was noticed with compound (1) with an inhibition area diameter of only 11 mm compared to the standard sample.

As made evident by the data of the anti-microbial tests the sensitivity/resistance of the microorganisms is different toward the tested compounds due to both the different chemical structures of the compounds and the different types of the micro-organisms under study differing in their cell ultra-structures and response manner to the chemical compounds: Gram-positive bacteria (*Staphylococcus aureus*), Gram-negative bacteria (*Escherichia coli*) and yeasts (*Candida albicans*).

The obtained results are indicative of an increased sensitivity of the *Escherichia coli* bacterium and as and yeasts (*Candida albicans*) to the tested compounds.

Conclusions

The original results reported herein were obtained by testing the newly obtained compounds which revealed potential anti-microbial action.

According to the results of the study the compounds present antimicrobial effects against Gram-positive, Gram-negative bacteria and on yeasts.

The antimicrobial activity was estimated by measuring the growth inhibition area against types of microorganism strains.

The antibacterial activity was detected in the case of the compounds tested, demonstrating that substituents, can influence this activity.

The antimicrobial activity towards some micro-organisms presented by this compounds, provides useful information for potential therapeutic use.

References

- [1] S. M. Alam, J. H. Choi and D. U. Lee, *Synthesis of novel Schiff analogues of 4-amino-1,5-dimethyl-2-phenylpyrazol-3-one and their evaluation for antioxidant and anti-inflammatory activity*, *Bioorg Med Chem.*, 2012, 20, pp. 4103-4108.

- [2] A. Bruno, S. Tacconelli and P. Patrignani, *Variability in response to non-steroidal anti-inflammatory drugs: Mechanism and perspectives*, **Basic Clinical Pharmacol Toxicology**, 2014, 114, pp. 56-63.
- [3] J. Slawinski and Z. Brzozowski, *Synthesis and in vitro antitumor activity of novel series 2-benzylthio-4-chloro-benzenesulfonamide derivatives*, **Eur. J. of Med. Chem.**, 2006, 41, pp. 1180-1189.
- [4] A. K. Ghosh, E. Pretzer, H. Cho, K. A. Hussain and N. Duzguiness, *Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease*, **Antivir. Res.**, 2002, 54, pp. 29-36.
- [5] G. Mariappan, B. P. Saha, L. Sutharson, L. Pandey and D. Kumar, *The diverse pharmacological importance of Pyrazolone Derivatives: A Review*, **J. Pharm. Res.**, 2010, 3(12), pp. 2856-2859.
- [6] P. P. N. Rao, S. N. Kabir and T. Mohamed, *Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development*, **Pharmaceuticals**, 2010, 3, pp. 1530-1549.
- [7] M. Apotrosoaei, I. Vasincu, O. Drăgan, F. Buron, S. Routier and L. Profire, *Design, synthesis and the biological evaluation of 1,3-thiazolidine-4ones based on 4-amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5one scaffold*, **Molecules**, 2014, 19(9), p. 13824-13847.
- [8] A. M. Mocanu, C. Luca, S. I. Dunca and G. Ciobanu, *Antibacterial activity of some new hydrazide derivatives with potential biological action*, **Rev. Chim.** (Bucharest), 2014, 65 (11), pp. 1363-1368.
- [9] A. M. Mocanu, C. Luca, I. Sandu, S. I. Dunca, *Synthesis, characterization and evaluation antimicrobial activity of some new derivatives theophylline sulfonyl phenoxyacetic acids*, **Rev. Chim.** (Bucharest), 2016, 67 (3), pp. 584-588.
- [10] A. M. Mocanu, C. Luca, G. Ciobanu, S. I. Dunca, I. G. Sandu and A. C. Luca, *Synthesis, Characterization and Antimicrobial Activity of Some New Hydrazine Metallic Complexes*, **Rev. Chim.** (Bucharest), 2015, 66 (8), pp. 1137-1142.
- [11] Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, M100-22: 32, 2012.
- [12] G. A. Wistreich, *Microbiology Laboratory Pretince Hall Upper Saddle River*, New Jersey, 2000.
- [13] A. G. Grigoraş, Ş. Racoviţă, S. Vasiliu, M. T. Nistor, S. I. Dunca, V. Bărboiu and V.C. Grigoraş, *Dilute solution properties of some polycarboxybetaines with antibacterial activity*, **J. Polym. Res.**, doi: 10.1007/s10965-012-0008-1, 2012.
- [14] A. M. Mocanu, C. Luca and A. C. Luca, *Synthesis, Characterization and Thermal Degradation of Some New 3,5-dimethyl Pyrazole Derivatives*, **Rev. Chim.** (Bucharest), 2017, 68 (2), pp. 317-322.

Received: February 6, 2018

Accepted: April 22, 2018